Algorithmic scheme for prescribing choline alfoscerate in the treatment of cognitive impairment

Algorithmic scheme for prescribing choline alfoscerate in the treatment of cognitive impairment

O.A. Shavlovskaya

Olga A. Shavlovskaya, e-mail: shavlovskaya@1msmu.ru

International University of Restorative Medicine, Moscow 

Findings from multiple studies conducted in both inpatient and outpatient clinical settings have demonstrated the high efficacy and favorable safety profile of choline alfoscerate (CA) in patients with mild to moderate cognitive impairment (CI), amnestic-type CI, predementia cognitive impairment associated with Alzheimer’s disease (AD), as well as in elderly individuals and first-degree relatives of patients with AD, in whom the drug may be used as a preventive intervention. The Russian formulation of CA (Cereton) is available in several dosage forms, including a solution for intravenous and intramuscular administration, capsules, and an oral solution, thereby allowing treatment to be tailored to the individual patient’s clinical condition. In the inpatient setting, the course of injectable treatment with Cereton generally lasts 10–15 days, after which patients are transitioned to oral therapy for up to 90 days (with the possibility of extending treatment to 180 days). The duration of therapy and the dosage of Cereton in capsule form or as an oral solution depend on the patient’s age and the severity of the condition. The oral solution may be prescribed for children aged 6 years and older, whereas capsules may be used from 11 years of age, with treatment courses of up to 60 days. Treatment with Cereton is carried out in two stages: the first stage involves intravenous or intramuscular administration, and the second stage consists of oral treatment with either capsules or oral solution. The drug is generally well tolerated, and adverse events are infrequent and typically mild.

Keywords: cognitive impairment, cerebrovascular diseases, advanced age, post-stroke cognitive impairment, choline alfoscerate, Cereton.

For citation: Shavlovskaya O.A. Algorithmic scheme for prescribing choline alfoscerate in the treatment of cognitive impairment. RMJ. 2026;4:31–34. DOI: 10.32364/2225-2282-2026-4-7